

Product list Ophthalmics

July 2025



Farmaprojects polpharma group

Ophtalmics available

| INN | STRENGTH | Shelf Life | PRESERVA TIVE FREE | PRESENTATIO N | THERAPY DAYS | STABILITY ZONE II | STABILITY ZONE IV | PRODU CT ML | STORAGE CONDITIONS | BATCH SIZE |
|---|----------------------|------------------|-----------------------|---------------------|-----------------|----------------------|----------------------|----------------|---|------------------|
| Anti-allergy (Eye drops solution) | | | | | | | | | | |
| Olopatadine | 1mg/ml | 36 mont hs | Yes | Nemera Novelia ® | 30 90 | Yes Yes | No TBD | 5.0 3 x 5.0 | Store below 30oC. After first opening use in 90 days. | 43 860 |
| Anti- infectives Eye (Eye drops solution) | | | | | | | | | | |
| Moxifloxacin | 5mg/ml | 24 mont hs | No | Regular bottle | 30 | Yes | No | 5 | Once opened - store for 28 days at a temperature below 30oC | 40 000 |
| Glaucoma (Eye drops solution) | | | | | | | | | | |
| Bimatoprost | 0.3mg /ml | 24 mont hs | Yes | Nemera Novelia ® | 30 | Yes | No | 3 | Once opened, do not store above 25oC | 70 423 25 510 |
| Bimatoprost/ Timolol | (0.3mg / 5mg) /ml | 24 mont hs | Yes | Nemera Novelia ® | 30 90 | Yes | No | 3 | Once opened, do not store above 25oC | 70 423 25 510 |
| Brimonidine | 2mg /ml | 24 mont hs | Yes | Nemera Novelia ® | 30 90 | Yes Yes | No No | 5.0 3 x 5.0 | Store below 30oC. After first opening use in 90 days. | 43 103 43 103 |

*Polpharma Group API CA:

Dossier suitable for Canadian market Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subjected to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer's responsibility and liability to check the patent situation of the poduct in the import market(s).

| Dorzolamide | 20mg/ml | 24 mont hs | Yes | Nemera Novelia ® | 30 60 | Yes Yes | No No | 5.0 10.0 | Once opened, do not store above 25oC | 45 455 22 727 |
|-----------------------------------|------------------------|------------------|-------------------|----------------------------------|----------------------------|----------------------------|----------------------------|----------------|--|--------------------|
| Dorzolamide/Ti molol | (20mg/5m g) /ml | 24 mont hs | Yes | Nemera Novelia ® | 30 60 | Yes Yes | No No | 5.0 10.0 | Once opened, do not store above 25oC | 45 455 22 727 |
| Latanoprost | 0,05mg /ml | 24 mont hs | Yes | Aeropump 3K ® | 30 90 | Yes Yes | In progress In progress | 2.5 7.5 | Do not freeze. Do not store above 25oC Zone IV- 90 days in use study in progress. | 54 000 18 000 |
| Latanoprost/Ti molol | (0.05mg / 5mg) / ml | Yes | Aeropum p 3K ® | 30 90 | In progress In progress | 2.5 7.5 | 54 000 18 000 | | | |
| Travoprost | 0.04mg / ml | 24 mont hs | Yes | Aeropump 3K ® | 30 90 | Yes Yes | In progress In progress | 2.5 7.5 | Do not freeze. After first opening keep the bottle in the outer carton in order to protect from light. | 55 000 22 000 |
| Travoprost/Ti molol | (0.04mg / 5mg) / ml | 24 mont hs | Yes | Aeropump 3K ® | 30 90 | In progress In progress | In progress In progress | 2.5 7.5 | Do not freeze. After first opening keep the bottle in the outer carton in order to protect from light. | 55 000 22 000 |
| Acetazolamide | 250mg | 60 mont hs | No | Tablets | 30 | No | No | - | 300 000 | |
| Tropicamide | 5mg/ml 10mg / ml | 36 mont hs | No No | Regular bottle Regular bottle | 30 30 | Yes Yes | No No | 2 x 5 2 x 5 | Store below 25oC. After first opening use in 4 weeks. | 192 000 594 000 |
| Tobramycin / Dexamethaso ne | (3mg +1mg) /ml | 24 mont hs | No | Regular bottle | 30 | Yes | No | 5 | Store below 25oC. After first opening use in 4 weeks. | 40 000 |

*Polpharma Group API CA:

Dossier suitable for Canadian market Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subjected to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer's responsibility and liability to check the patent situation of the poduct in the import market(s).

Ophtalmics under development

| INN | INDICATION | DEVELOPMENT PHASE |
|------|------------|-------------------|
| | | |
| OR11 | Red eye | Lab development |
| OD41 | Dry eye | Lab development |
| OD31 | Dry eye | Lab development |
| OIII | Infection | Lab development |
| O21 | Glaucoma | Lab development |

*Polpharma Group API CA:

Dossier suitable for Canadian market Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subjected to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer's responsibility and liability to check the patent situation of the poduct in the import market(s).



FARMAPROJECTS SAU

Carrer Provença 392, 6ª Planta 08025 Barcelona (Spain) Phone +34 93 508 05 00 email: sales@farmaprojects.com

www.farmaprojects.com



